MASH drug developers spike as FDA accept a proposal for a non-invasive surrogate endpoint for clincal trials targeting the liver disease.
https://seekingalpha.com/news/4489702-fda-accepts-lenient-mash-trial-requirement
MASH drug developers spike as FDA accept a proposal for a non-invasive surrogate endpoint for clincal trials targeting the liver disease.
https://seekingalpha.com/news/4489702-fda-accepts-lenient-mash-trial-requirement
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.